文献速递中医儿科中药与中成药合理使用

中药汤剂联合常规疗法治疗儿童哮喘的网络Meta分析

Efficacy of traditional Chinese medicine decoctions combined with conventional therapy for pediatric asthma: a network meta-analysis.
PubMed 文献 · Front Pharmacol · 2026-06-25

该研究采用贝叶斯网络Meta分析,系统检索7个数据库至2025年3月24日的随机对照试验,评估中药汤剂联合常规西医治疗与单用常规治疗对儿童哮喘的疗效。共纳入21项RCT、2068例患者和9种汤剂。与单用常规治疗相比,清肺化痰汤联合治疗显著改善FEV1(MD 1.20,95%CrI 1.10–1.40),麻杏石甘汤联合治疗显著提高PEF(MD 12.00,95%CrI 8.00–17.00);但纳入研究存在较高偏倚风险,结论应视为初步探索性。

要点

  • 清肺化痰汤联合常规治疗在改善FEV1方面排名最高(SUCRA=99.9%)。
  • 麻杏石甘汤联合常规治疗在提高PEF方面排名最高(SUCRA=97.1%)。
  • 纳入研究普遍缺乏盲法和分配隐藏,证据质量有限。

核心结论

  • 与单用常规西医治疗相比,清肺化痰汤联合治疗显著改善FEV1,麻杏石甘汤联合治疗显著提高PEF,但证据受方法学限制,应视为初步假设。

研究设计与样本

  • 贝叶斯网络Meta分析,系统检索7个数据库至2025年3月24日的RCT,最终纳入21项RCT、2068例患者和9种中药汤剂。

主要发现

  • 清肺化痰汤联合常规治疗对比单用常规治疗改善FEV1的MD为1.20(95%CrI 1.10–1.40)。
  • 麻杏石甘汤联合常规治疗对比单用常规治疗提高PEF的MD为12.00(95%CrI 8.00–17.00)。
  • SUCRA排名:清肺化痰汤联合治疗对FEV1的SUCRA为99.9%,麻杏石甘汤联合治疗对PEF的SUCRA为97.1%。
  • 敏感性分析显示FVC和IgG结果稳定,麻杏石甘汤合苏亭丸联合治疗和小青龙汤联合治疗在所有分析中排名第一。
  • 对IgE,没有任何汤剂显示统计学显著差异,且排名对分析条件敏感。

临床怎么用

  • 在儿童哮喘常规西医治疗基础上,可考虑联合清肺化痰汤或麻杏石甘汤以改善肺功能指标。
  • 应充分告知患者及家属证据的初步性和方法学局限性,避免过度解读排名。

局限性

  • 所有纳入研究存在高或不明确的偏倚风险,尤其缺乏分配隐藏和盲法。
  • 无法完全确保不同中药汤剂之间的可比性,结果应视为假设生成和探索性。
  • 对IgE无显著差异且排名不稳定,PEF敏感性分析排名受合格治疗数量减少影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to explore the potential comparative effectiveness of various traditional Chinese medicine (TCM) decoctions plus conventional biomedical treatment (CBT) versus CBT alone in pediatric asthma using a Bayesian network meta-analysis (NMA). METHODS: Seven databases were systematically searched for randomized controlled trials (RCTs) published up to 24 March 2025 that evaluated TCM decoctions in the treatment of pediatric asthma. The Bayesian NMA was conducted using R 4.4.1 and Stata 15.1. Risk of bias was assessed using the Cochrane tool (Review Manager 5.4.1), and interventions were tentatively ranked by surface under the cumulative ranking curve (SUCRA). RESULTS: A total of 21 RCTs involving 2,068 patients and 9 distinct TCM decoctions were included. The risk of bias was high or unclear in all studies included, with particular concerns regarding allocation concealment and blinding. Compared with CBT alone, Qing Qi Hua Tan Tang (QQHTT) + CBT significantly improved forced expiratory volume in one second (FEV1) (mean difference [MD] 1.20; 95% credible interval [CrI] [1.10, 1.40]). Ma Xing Shi Gan Tang (MXSGT) + CBT significantly increased peak expiratory flow (PEF) (MD 12.00; 95% CrI [8.00, 17.00]). According to SUCRA, QQHTT + CBT (SUCRA = 99.9%) and MXSGT + CBT (SUCRA = 97.1%) ranked highest for FEV1 and PEF. CONCLUSION: Sensitivity analyses confirmed the stability of the results regarding FVC and IgG, with Ma Xing Shi Gan Tang He Su Ting Wan (MXSGTHSTW) + CBT and Xiao Qing Long Tang (XQLT) + CBT which was ranked first in all analyses. For FEV1, the top-ranked interventions (QQHTT, Da Qing Long Tang [DQLT], MXSGTHSTW) remained in the top three across all analyses, with minor changes in ranking attributable to differences in inclusion criteria across studies. For PEF, the rankings in sensitivity analysis 1 were influenced by a reduction in the number of eligible treatments. For IgE, no decoction showed statistically significant differences, and the rankings were sensitive to the conditions of the analysis. Although QQHTT and MXSGT demonstrated statistical advantages in this NMA, serious methodological limitations exist in the included studies, particularly the lack of blinding and allocation concealment. Moreover, the inability to fully ensure the comparability of TCM decoctions means that these findings should be regarded as preliminary, hypothesis-generating and exploratory. SYSTEMATIC REVIEW REGISTRATION: identifier CRD420251120217.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Zhao Y, Li M, Ai A, et al. Efficacy of traditional Chinese medicine decoctions combined with conventional therapy for pediatric asthma: a network meta-analysis. Front Pharmacol. 2026. PMID: 42428505. doi:10.3389/fphar.2026.1780354

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。